Exelixis, Inc. $EXEL Shares Bought by denkapparat Operations GmbH

denkapparat Operations GmbH raised its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 38.5% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 33,152 shares of the biotechnology company’s stock after acquiring an additional 9,222 shares during the quarter. Exelixis comprises approximately 0.6% of denkapparat Operations GmbH’s investment portfolio, making the stock its 25th largest holding. denkapparat Operations GmbH’s holdings in Exelixis were worth $1,804,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of EXEL. Motiv8 Investments LLC purchased a new stake in shares of Exelixis during the fourth quarter worth $26,000. Cassaday & Co Wealth Management LLC purchased a new position in Exelixis in the first quarter valued at $27,000. Western Wealth Management LLC acquired a new position in Exelixis during the 1st quarter worth $29,000. Acumen Wealth Advisors LLC purchased a new stake in Exelixis during the 4th quarter worth about $29,000. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Exelixis by 1,380.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 773 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Buying and Selling

In other Exelixis news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the transaction, the director directly owned 16,079 shares in the company, valued at $862,799.14. This represents a 37.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is owned by corporate insiders.

Exelixis Price Performance

Exelixis stock opened at $59.13 on Friday. The stock has a market cap of $14.65 billion, a PE ratio of 18.59, a P/E/G ratio of 1.74 and a beta of 0.42. The stock’s fifty day moving average is $54.98 and its two-hundred day moving average is $49.44. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $59.72.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The business had revenue of $628.69 million during the quarter, compared to analysts’ expectations of $636.40 million. During the same period in the prior year, the firm posted $0.75 EPS. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, research analysts expect that Exelixis, Inc. will post 3.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on EXEL. Wells Fargo & Company increased their price target on Exelixis from $40.00 to $49.00 and gave the company an “equal weight” rating in a research report on Monday, July 13th. Stifel Nicolaus upped their target price on shares of Exelixis from $47.00 to $51.00 and gave the stock a “hold” rating in a research note on Thursday, August 6th. Royal Bank Of Canada raised their target price on shares of Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Zacks Research upgraded shares of Exelixis from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Finally, UBS Group set a $55.00 price target on shares of Exelixis in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $50.07.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.